key: cord-0698848-9ttajlfs authors: Denholm, Justin T.; Davis, Joshua; Paterson, David; Roberts, Jason; Morpeth, Susan; Snelling, Thomas; Zentner, Dominica; Rees, Megan; O’Sullivan, Matthew; Price, David; Bowen, Asha; Tong, Steven Y. C. title: The Australasian COVID-19 Trial (ASCOT) to assess clinical outcomes in hospitalised patients with SARS-CoV-2 infection (COVID-19) treated with lopinavir/ritonavir and/or hydroxychloroquine compared to standard of care: A structured summary of a study protocol for a randomised controlled trial date: 2020-07-14 journal: Trials DOI: 10.1186/s13063-020-04576-9 sha: dc5e9d1f8fa6d39d5337ac0db107cb14d9243fa7 doc_id: 698848 cord_uid: 9ttajlfs OBJECTIVES: To determine if lopinavir/ritonavir +/- hydroxychloroquine will reduce the proportion of participants who survive without requiring ventilatory support, 15 days after enrolment, in adult participants with non-critically ill SARS-CoV-2 infection. TRIAL DESIGN: ASCOT is an investigator-initiated, multi-centre, open-label, randomised controlled trial. Participants will have been hospitalised with confirmed COVID-19, and will be randomised 1:1:1:1 to receive lopinavir /ritonavir, hydroxychloroquine, both or neither drug in addition to standard of care management. PARTICIPANTS: Participants will be recruited from >80 hospitals across Australia and New Zealand, representing metropolitan and regional centres in both public and private sectors. Admitted patients will be eligible if aged ≥ 18 years, have confirmed SARS-CoV-2 by nucleic acid testing in the past 12 days and are expected to remain an inpatient for at least 48 hours from the time of randomisation. Potentially eligible participants will be excluded if admitted to intensive care or requiring high level respiratory support, are currently receiving study drugs or their use is contraindicated due to allergy, drug interaction or comorbidities (including baseline QTc prolongation of 470ms for women or 480ms for men), or death is anticipated imminently. INTERVENTION AND COMPARATOR: Participants will be randomised 1:1:1:1 to: Group 1: standard of care; Group 2: lopinavir (400mg) / ritonavir (100mg) twice daily for 10 days in tablet form; Group 3: hydroxychloroquine (800mg) 4x200mg administered 12 hours apart on Day 1, followed by 400mg twice a day for 6 days; Group 4: lopinavir /ritonavir plus hydroxychloroquine. MAIN OUTCOMES: Proportion of participants alive and not having required intensive respiratory support (invasive or non-invasive ventilation) at 15 days after enrolment. A range of clinical and virological secondary outcomes will also be evaluated. RANDOMISATION: The randomisation schedule will be generated by an independent statistician. Randomisation will be stratified by site and will be in permuted blocks of variable block size. The randomised sequence allocation will only be accessible to the data management group, and site investigators will have individual participant allocation provided through a web-based trial enrolment platform. BLINDING (MASKING): This is an open-label study, with researchers assessing the laboratory outcomes blinded to treatment allocation. No unblinding procedures relating to potential adverse effects are therefore required. NUMBERS TO BE RANDOMISED (SAMPLE SIZE): We assumed that 5% of participants receiving standard of care would meet the primary outcome, aimed to evaluate whether interventions could lead to a relative risk of 0.5, assuming no interaction between intervention arms. This corresponds to a required sample size of 610 per arm, with a 5% two-sided significance level (alpha) and 80% power. The total sample size therefore is planned to be 2440. TRIAL STATUS: ASCOT protocol version 3, May 5, 2020. Recruitment opened April 4, 2020 and is ongoing, with planned completion of enrolment July 31, 2021. TRIAL REGISTRATION: Australian New Zealand Clinical Trials Registry (ACTRN12620000445976). Prospectively registered April 6, 2020. FULL PROTOCOL: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol. Open label, multi-centre, randomized controlled trial (RCT) Standard of care without specific antiviral therapy Lopinavir (400mg) / ritonavir (100mg) (LPV/r) twice daily for 10 days OR Hydroxychloroquine 800mg twice a day for 1 day, followed by 400mg two times a day for 6 days OR LPV/r PLUS hydroxychloroquine in the above regimens April 2020 onwards Flexible (see sample size section for justification) 1. Age ≥ 18 years 2. Confirmed SARS-CoV-2 by nucleic acid testing in the past 12 days 3. Able to be randomised within 12 days of symptom onset 4. Expected to be remain an inpatient for at least 48 hours from the time of randomisation EXCLUSION CRITERIA 1. Currently admitted to an Intensive Care Unit (ICU) or a hospital area that is functioning as an ICU 2. Currently receiving acute intensive respiratory support (invasive or non-invasive ventilation). Note that participants already on noninvasive ventilation (either CPAP or BiPAP) in the community can still be recruited if they are continuing on their usual degree of NIV. 3. Currently taking LPV/r OR hydroxychloroquine 4. Known allergy or hypersensitivity to LPV/r OR hydroxychloroquine 5. Use of medications that are contraindicated with lopinavir/ritonavir OR hydroxychloroquine that cannot be replaced or stopped during the study period (see Table 1 and https://www.covid19druginteractions.org/) 6. Currently on other investigational agents with targeted antiviral effects 7. Known cirrhosis or ALT or AST > 5x upper limit of normal 8. Previous participation in the trial 9. Known pregnancy 10. Known HIV infection not on antiretroviral therapy 11. QTc ≥470ms for males, QTc ≥480ms for females 12. Treating team deems enrolment in the study is not in the best interest of the patient 13. Death is deemed to be imminent and inevitable within the next 24 hours RANDOMISATION Eligible participants will be randomized 1:1:1:1 in a factorial design. Randomization will be stratified by site and be in permuted blocks of variable size. This will be an open-label study. At this stage in the epidemic it is not clear the likely numbers of patients that will present to study sites. To detect a reduction in the primary endpoint from 5% to 2.5% would require a sample size of 2,440. To detect a reduction in the primary endpoint from 10% to 5% would require a sample size of 1,224. To detect a reduction in the primary endpoint from 15% to 10% would require a sample size of 1,740. Analysis of the primary outcome will be by modified intention to treat (all participants with data available for the primary endpoint will be analysed according to the treatment allocation, regardless of what treatment they received). A per protocol analysis will also be performed. The per protocol population is defined as 1) for the control group: did not receive any LPV/r or hydroxychloroquine; 2) for the intervention group: received at least 80% of possible doses of LPV/r AND/OR hydroxychloroquine; 3) has available data. We also plan pre-specified subgroup analyses for the following groups: a) Aged >65 or ≤65 years b) Participants receiving ACE inhibitor/ATII blocker therapy at the time of presentation c) Receipt of study drug within 96 hours of fever onset d) Receipt of study drug within 96 hours of first symptom onset e) Mild disease vs moderate disease I have read the protocol entitled "Australasian COVID-19 Trial (ASCOT)". By signing this protocol, I agree to conduct the clinical trial, after approval by a Human Research Ethics Committee or Institutional Review Board (as appropriate), in accordance with the protocol, the principles of the Declaration of Helsinki and the good clinical practice guidelines adopted by the TGA [Integrated Addendum to ICH E6 (R1): Guideline for Good Clinical Practice E6 (R2), dated 9 November 2016 annotated with TGA comments]. Changes to the protocol will only be implemented after written approval is received from the Human Research Ethics Committee or Institutional Review Board (as appropriate), with the exception of medical emergencies. I will ensure that trial staff fully understand and follow the protocol and evidence of their training is documented on the trial training log. There are no known effective therapeutic options at this stage. Clinical trials have begun for many agents including lopinavir/ritonavir (LPV/r) and hydroxychloroquine. While clinical trials in China initially provided an opportunity to assess the impact on clinical outcomes, there are now few reported cases in China. Clinical trials in Australia and New Zealand will have value in: 1) contributing to understanding of clinical efficacy in local healthcare settings; 2) allowing detailed assessments of virological and immunological outcomes in a blinded manner; 3) providing therapeutic options to Australian and New Zealand patients in the context of a clinical trial. SARS-CoV-2 causes a clinically significant and transmissible respiratory tract infection. In a large case series patients commonly had fever, cough and evidence of pneumonia on chest xray 1 . Several broad approaches to improving outcomes for severe viral infections can be considered, beyond optimal supportive care as appropriate. These approaches may include host immune modulation (for example, with the use of treatments such as steroids to reduce inflammation, or immune globulin to enhance specific responses), or interventions which aim to interfere with viral activity. Several antiviral medications have been previously investigated in clinical and laboratory studies for Sudden Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS), diseases caused by related coronaviruses (SARS-CoV and MERS CoV respectively). These have not established definite efficacy for these coronaviruses, but have suggested potential benefit from the use of LPV/r with or without interferon B 2-4 . Other antivirals, including ribavirin, appear to have been associated with increased mortality and are not considered suitable candidates for SARS-CoV-2. As SARS-CoV-2 is a novel viral pathogen, little clinical trial data on antiviral therapy and impact on outcomes exists. Laboratory studies have demonstrated that several agents, including chloroquine and LPV/r, have activity in vitro against SARS-CoV-2 5 . Remdesivir, a novel nucleoside analogue, has been shown to have in vitro activity against a range of coronaviruses, but is not in clinical use 5, 6 . One recently published study reported improvement in time to clinical improvement in the group receiving LPV/r, but no statistically significant improvement in mortality 7 . However, the study was substantially underpowered to detect an effect, and a large randomised trial is needed to establish the efficacy of LPV/r in hospitalised patients infected with SARS-CoV-2. WHO have recommended that specific treatments for COVID-19 should not be occurring outside of clinical trials given the current lack of evidence and potential for harm of therapeutic agents. As outlined above, LPV/r and chloroquine have both had in vitro demonstration of effectiveness against SARS-CoV-2 replication 5 . Both medications are currently available for use in Australia and New Zealand for other indications and have well-established safety profiles. Activities (EC50s) of hydroxychloroquine against the SAR-CoV-2 virus are in the low micromolar range 8 which represents the upper end of the free plasma concentration range encountered in clinical practice. Extensive advice has been sought from those with experience in using chloroquine for malaria. Chloroquine and hydroxychloroquine have unusual pharmacokinetic properties. Absorption after oral administration is rapid and generally reliable but the total apparent volume of distribution is enormous (>100 L/kg) reflecting extensive tissue binding. The initial plasma or whole blood concentration profile in the treatment of acute illness is determined mainly by distribution processes and not by elimination. This is critical to understanding dosing and concentration profiles and associated risks with short course treatments. In the treatment of malaria (or COVID19) the initial (loading) doses are designed to "fill" the body so that concentrations that would take weeks to achieve without a loading dose, are achieved as soon as safely possible. To achieve blood levels of hydroxychloroquine above the in vitro IC50-value for SARS-CoV-2 (1.13 μM) 8 , high loading doses of hydroxychloroquine are required. Simulated blood concentration time profiles of hydroxychloroquine using pharmacokinetic models suggest that two large loading doses of 800mg in the first day are required, followed by 400mg bd for subsequent days (Professor Nicholas White, personal communication). These doses are above the currently recommended doses from the Therapeutic Goods Administration in Australia for general use of hydroxychloroquine. It is important to note that many of the reported adverse events (AEs) of LPV/r relate to longer term use and are very unlikely to be an issue with a 10-day course -this includes hyperlipidaemia, redistribution of body fat and hyperglycaemia. Furthermore, most data come from patients with HIV infection, who are unlikely to be representative of those being treated for COVID-19. Considering short term use, commonly reported adverse effects include diarrhoea and nausea. In the recent RCT among 199 COVID-19 patients 7 , nausea was reported in 9.5% in the LPV/r group and 0% in the control group, vomiting in 6.3% versus 0%, and diarrhoea in 4.2% versus 2.1%. Diarrhoea was severe (grade 3 or 4) in no patients, and nausea/vomiting in only 1. In the product information, rare but serious AEs include hepatitis, pancreatitis, QT interval prolongation and PR interval prolongation -however it is noted that a definite causal relationship has not been established for any of these. In the Cao et al trial, none of these more serious AEs occurred at a higher frequency in the LPV/r arm than in the control arm, apart from prolonged QTc, which occurred in 1 patient (1.1%) in the LPV/r arm and none in the control arm 7 . Key features of the safety profile of hydroxychloroquine (HCQ) Similar principles apply to HCQ. Many of the reported AEs relate to long term use. Retinopathy and neuromyopathy are both reported, but relate to the total cumulative dose, and monitoring for these is only recommended in those on long term therapy (meaning more than one year). Serious but rare AEs which could be relevant with shorter courses include prolonged QT interval (and resultant arrhythmias), hypoglycaemia (generally with concomitant diabetes treatments), and pancytopenia. Although there is little experience to date in the treatment of COVID19 the extensive previous experience in acute malaria suggests that serious toxicity (hypotension, arrhythmias, convulsions) should be unlikely at the doses being used. Common and less serious AEs include nausea and vomiting, vertigo, tinnitus and rash. Chloroquine and hydroxychloroquine can block the inwardly rectifying Kir2.1 potassium (hERG) channel which delays ventricular repolarization and results in electrocardiographic QT prolongation. This is a risk factor for polymorphic ventricular tachycardia (TdP: torsade de pointes) but it is currently unclear whether the risk of TdP is actually increased with chloroquine or hydroxychloroquine. An assessment of the tolerability of chloroquine (and by extrapolation likely tolerability of hydroxychloroquine at high dose) as used for uncomplicated malaria in the IMPROV study 9 has been provided to the ASCOT protocol writing group. Among patients treated with chloroquine at doses of 10mg/kg in the first day (either as a single dose or two divided doses) acute vomiting within 60 minutes occurred in 22/1,322 (1.7%), vomiting in the first 24 hours in 94/1355 (7%), nausea in the first 24 hours in 200/1346 (14.9%), and diarrhoea in the first 24 hours in 25/1352 (1.9%). If there is significant gastrointestinal intolerance with the hydroxychloroquine 400mg bd maintenance dose, then the dose can be reduced to 200mg bd. The key AE of concern with combination use of these two drugs is prolonged QT interval and resultant arrhythmias. There are no clinical data on combining these two drugs. We have built in extra exclusion criteria (baseline prolonged (QTc), monitoring (ECGs) and stopping rules (prolonged QTc) because of this. Due to the high doses of hydroxychloroquine and combination with LPV/r, there will be additional monitoring of specific AEs. Specifically: • Assessment of gastrointestinal intolerance (nausea, vomiting, diarrhoea) within the first 4 hours of the initial drug administration. • Recommendation to check and correct electrolyte abnormalities of K+ (aiming for ≥4.0 mmol/L) and Mg++ (aiming for ≥0.7 mmol/L) • For the first 100 patients, ECGs will be obtained at baseline, 4 hr, 24 hr and day 4 after initial drug administration. Study drugs will be ceased if QTc >500ms or QTc >60ms (compared to baseline). A cardiac electrophysiologist will independently review all baseline, 4 hr, 24 hr and day 4 ECGs in a blinded fashion for the first 100 patients to compare this 'gold standard' assessment with the automated ECG reading. The findings from this initial analysis of QTc will be reported to the DSMB. If there are no concerning safety signals, the 4 hr ECG will not be required for the rest of the trial. • Specific collection of data on the occurrence of cardiac arrhythmias until the time of hospital discharge or in-hospital death It is expected that a substantial number of Australian and NZ residents may be infected with SARS-CoV-2, and based on international experience, a significant proportion will require hospitalisation (up to 20%) and be at risk for intensive care admission (up to 5%) and death (~1%). No established treatment to prevent these poor outcomes exists, and ASCOT will provide a controlled trial environment for two candidate medications to be used and evaluated. The ASCOT study will allow for the efficacy and safety of these medications, alone and in combination, to be considered under closely monitored conditions. Even if the study does not recruit sufficient numbers in itself for definitive conclusions for the primary endpoint of alive and not having required invasive or non-invasive ventilation at 15 days, it will contribute to broader global understanding and contribute to meta-analyses with other trials. It will also be important to determine the efficacy and safety of trial interventions within an Australasian context as the healthcare standards may differ from that of trials conducted elsewhere. Furthermore, detailed collection of samples will provide virological and immunological mechanistic insights into the efficacy or lack of efficacy of trial interventions. An underlying principle is that we should provide randomised care rather than random care. At this stage, it is unknown whether the agents to be tested will provide benefit, harm or neither. There may be limited supply of these agents and until there is clear evidence of benefit or harm, the most judicious use is within the context of a clinical trial. We hypothesise that treatment with LPV/r +/-hydroxychloroquine will lead to improved clinical outcomes for hospitalised patients with SARS-CoV-2 infection. To determine if LPV/r +/-hydroxychloroquine will reduce the proportion of participants who survive without requiring invasive or non-invasive ventilation, 15 days after enrolment, in adult participants with non-critically ill SARS-CoV-2 infection. ASCOT is an investigator-initiated, multi-centre, open-label, randomised controlled trial. The study design will allow harmonisation with existing frameworks such as the Sentinel Travellers Research Preparedness Platform for Emerging Infectious Diseases (SETREP-ID, PI Thevarajan) and the Randomized, embedded, multifactorial adaptive platform trial for communityacquired pneumonia (REMAP-CAP) study (CI Steve Webb). Patients enrolled in ASCOT and who progress to requiring invasive or non-invasive ventilation can be enrolled in REMAP-CAP. As it is too early to accurately predict the size and distribution of the SARS-CoV-2 epidemic the feasibility and sample size requirements of the study will be progressively considered. In the initial design, consented participants will be randomised 1:1:1:1 on day 1 to receive either i) standard of care without LPV/r or hydroxychloroquine, ii) LPV/r; iii) hydroxychloroquine, or iv) LPV/r + hydroxychloroquine. For patients that are clinically worsening at day 5 or beyond, the protocol allows for (but does not encourage) the treating clinician to commence LPV/r +/-hydroxychloroquine from day 5 onwards. Daily data will be collected for the first 15 days or until discharge, whichever is earlier. There will be a core dataset collected for all patients at all sites and enhanced and research data and biological samples for sites with capacity. Data will be harmonised with the ISARIC SARS-CoV-2 and REMAP-CAP protocols and CRFs (https://isaric.tghn.org/novelcoronavirus/). As long as the participant remains an inpatient, their medical records will be reviewed weekly until discharge or the 90-day time point, whichever occurs first. We are aiming to recruit from sites across Australia and NZ. Sites will be selected on the basis of: i) Estimated (or known) numbers of cases with a focus on larger sites; ii) the availability of a committed principal site investigator and site research team; and iii) capacity to collect samples as per the protocol. 3. Able to be randomised within 12 days of symptom onset; 4. Expected to be remain an inpatient for at least 48 hours from the time of randomisation. 1. Currently admitted to an Intensive Care Unit (ICU) or a hospital area that is functioning as an ICU; 2. Currently receiving acute intensive respiratory support (invasive or non-invasive ventilation). Note, participants already on non-invasive ventilation (either CPAP or BiPAP) in the community can still be recruited if they are continuing on their usual degree of NIV. Humidified high flow nasal oxygen will not be considered an exclusion criterion. 3. Currently taking LPV/r OR hydroxychloroquine 4. Known allergy or hypersensitivity to LPV/r OR hydroxychloroquine 5. Use of medications that are contraindicated with LPV/r OR hydroxychloroquine that cannot be replaced or stopped during the study period. (see table 1 and https://www.covid19-druginteractions.org/) 6. Currently on other investigational agents with targeted antiviral effects 7. Known cirrhosis or ALT or AST > 5x upper limit of normal 8. Previous participation in the trial 9. Known pregnancy 10. Known HIV infection not on antiretroviral therapy (see note below*) 11. QTc ≥470ms for males, QTc ≥480ms for females 12. Treating team deems enrolment in the study is not in the best interests of the patient 13. Death is deemed to be imminent and inevitable within the next 24 hours Participants will be randomised to either the standard of care arm (2.3.1) or active treatment factorial (2.3.2). The standard of care arm will receive usual clinical care without LPV/r or hydroxychloroquine. The day of randomisation is considered day 1 of treatment. Randomisation and allocation must occur within 12 days of index sample collection that detected SARS-CoV-2 and within 12 days of symptom onset. The LPV/r or hydroxychloroquine will be prescribed by a doctor from the treating team as delegated. Storage conditions of LPV/r and hydroxychloroquine supplied by the Sponsor will be monitored for the study purposes. In the cases where institutional pharmacies have supplied LPV/r and/or hydroxychloroquine then the storage conditions will not be monitored. The participant's drug charts (electronic and/or paper) will be reviewed for compliance with study treatment. Any missed dose/s in the active treatment arms, and any use of LPV/r or hydroxychloroquine in the standard of care arm will be recorded on the CRFs. Treating physicians are encouraged to keep to the duration of treatment as per the protocol. If treatment is prolonged past the protocol defined duration this will be recorded. For the purposes of analysis, the participant will be included in the allocated treatment arm as for intention to treat analysis. The participant will not be included in the per protocol analysis if ≥2 additional days of treatment have been given. For participants who are enrolled into ASCOT AND who are taking an agent that is not on the contraindicated list (table 1) but that is potentially QT prolonging (table 2) , clinical judgement is required. Consideration should be given to: 1. The relative importance of that medication; a. Could the medication be easily replaced with something else? b. Is there any harm in stopping the medication for 7-10 days? 2. Other patient-specific risk factors, such as; a. electrolyte disturbance, or presence of diarrhoea or use of diuretics that might predispose to electrolyte disturbance b. ischaemic heart disease or cardiomyopathy, history of ventricular arrhythmia 3. Recent use of QT prolonging agents with a long half-life, such as amiodarone 4. The number of potentially QT prolonging agents the patient is taking 5. The QTc interval on the patient's ECG; if it is <470ms for males and <480 for females while on the medication/s then it is not a requirement to stop the medication/s in question in order to prescribe the trial antiviral agents. Note Azithromycin is not a contraindication to enrolment in ASCOT and use of hydroxychloroquine and/or lopinavir-ritonavir, but the considerations above should be thought through by the participant's clinical team. Participants will receive usual medical care. The protocol does not allow the use of LPV/r or hydroxychloroquine in the first 5 days. If at day 5 the treating team decides to prescribe LPV/r or hydroxychloroquine, this will be permitted within the protocol and recorded. However, such action is not encouraged as: 1. There is no evidence to support either benefit or harm of antiviral agents in this setting; 2. The WHO has a clear statement that use of unproven therapeutic agents should occur in the context of a clinical trial; 3. In the setting of limited drug supplies, use should be prioritised to address clinical questions; 4. Study drug supplied by the Sponsor for the study will not be used in these cases. Sites will be required to acquire to LPV/r or hydroxychloroquine from their local institutional pharmacy through normal prescribing channels. If LPV/r and / or hydroxychloroquine are used, the reasons for this decision will be recorded on the CRF and specifically will be: 1. Development of severe disease as per American Thoracic Guidelines for community acquired pneumonia as detailed in Table 3 2. Impending need for intensive respiratory support (invasive or non-invasive ventilation or humidified high flow nasal oxygen therapy) Use of LPV/r or hydroxychloroquine outside of these reasons and if prior to day 5 will be considered protocol violations and a specific reason will be recorded. Use of corticosteroids is discouraged 10 but recorded if used. Use of other potential therapies will also be discouraged but recorded if used. Antibiotic use will be recorded. For a more comprehensive list drugs which are QT prolonging agents https://www.covid19-druginteractions.org/ Hydroxychloroquine can be suspended and administered with the same dose and schedule as the tablet formulation. For participants who are unable to take medications by mouth, the LPV/r (400 lopinavir mg / 100 mg ritonavir) will be administered as a 5-ml suspension every 12 h via a pre-existing or newly placed nasogastric tube.. The Sponsor has been able to secure a limited stock of oral lopinavir/ritonavir solution. If during the study, the oral suspension is no longer available from the Sponsor, then the sites will be required to prescribe and administer study drug oral solutions as per the standard clinical pathways from their existing institutional stocks, otherwise refer to Appendix 3.4 for instructions on how to prepare oral suspensions. The dose of LPV/r is the standard dosing used for treatment of HIV.. Because LPV/r oral solution contains ethanol and propylene glycol, it is not recommended for use with polyurethane feeding tubes due to potential incompatibility. Feeding tubes that are compatible with ethanol and propylene glycol, such as silicone and polyvinyl chloride (PVC) feeding tubes, can be used. The initial dose of hydroxychloroquine is higher than the standard Australian recommendations (800mg/day max), which are for long term use. See section 1.2.4 for further details and rationale regarding the dosing of hydroxychloroquine. The schedule for dosing of hydroxychloroquine will be 800 mg, administered twice on day 1 only. Subsequently, the dose will be 400 mg administered twice daily for 6 days. If there is significant gastrointestinal intolerance with the hydroxychloroquine 400mg bd maintenance dose, then the dose can be reduced to 200mg bd. For participants who have renal impairment, but not on dialysis, there will be no alteration in the hydroxychloroquine dosing schedule. Participants who are on dialysis (both haemodialysis or Peritoneal Dialysis) will have their dosing schedule changed to hydroxychloroquine 800mg twice on Day 1 followed by 400mg once daily for 6 days. There is a risk of Torsades de Pointes with hydroxychloroquine and LPV/r and hence the study will exclude those with known QTC prolongation ≥470ms for males, QTc ≥480ms for females, and will monitor QTc during treatment. It is also recommended that electrolytes including Mg2+ should be checked at baseline and at day 2 and corrected if clinically indicated (aiming for K+ ≥ 4.0mmol/L and Mg2+ ≥ 0.70mmol/L. Consider discontinuing other medications that prolong QTc. See https://www.covid19-druginteractions.org (refer to table 2). The duration of treatment is based on the natural history of worsening of clinical status at approximately one week of illness for patients who develop more severe disease. Treatment for 10 days with LPV/r will therefore extend past this critical time point. Blood levels of hydroxychloroquine will continue to be above the EC50 for SARS-CoV-2 at a similar time point given the long terminal half-life of hydroxychloroquine. We have sourced study drugs from: -Mylan for lopinavir/ritonavir (oral tablet); -National Medical Stockpile (Australian Government) for Kaletra [lopinavir/ritonavir] (oral solution); and -Sanofi for hydroxychloroquine. These will be delivered to and stored at the Royal Brisbane and Women's Hospital (RBWH) pharmacy. RBWH pharmacy currently holds a cGMP license and has been accredited by the TGA as a COVID-19 central facility and will act as the central distribution warehouse for the ASCOT trial. During the early phase of the study sites will be able to prescribe and administer study drugs as per the standard clinical pathways from their existing institutional stocks. All study sites have clinical pharmacies that provide clinical dispensing to hospitalised patients. There will be a separate specific IMP management plan. Adjustment for renal function is not required for LPV/r or hydroxychloroquine. All site PIs will be trained in the study protocol, SOPs and their reporting requirements by the project manager, or a study chief investigator, prior to the site being opened for recruitment. All site PIs will need to have completed an accredited Good Clinical Practice training course. The project manager will have regular phone contact with all enrolling site investigators, including after the enrolment of participants number 1, 2 and 5 at each site, and every 10 participants thereafter. A sticker will be placed in the patient's medical record (one on the progress notes on the day of randomisation, and one in the front inside cover of the medical record ["old note"] if one exists). This sticker will alert clinicians that the patient has been randomised to the ASCOT study, with a brief explanation of the study. A copy of the study synopsis will be placed in the bedside chart (observations and drug chart) of the patient. A checklist of study procedures will also be placed in the bedside chart. For sites with electronic medical records and/or prescribing, an electronic "sticker" will be used, and appropriate annotations will be made to the electronic drug chart, or as per local institutional guidelines. The medication chart (be it paper or electronic) will be checked each day (apart from weekends) by the site PI or their delegate (registrar or research nurse) for the first 10 days whilst an inpatient to ensure adherence to the study protocol. Proportion of participants alive and not having new required intensive respiratory support (invasive or non-invasive ventilation) at 15 days after enrolment. This includes any participant who receives non-invasive mechanical ventilation (either CPAP or BIPAP) on the ward any time after enrolment even if not transferred to ICU. It does NOT include the use of humidified high-flow nasal prong oxygen. Participants on pre-existing home BiPAP or CPAP will not be considered to have met the primary endpoint unless they have either required invasive mechanical ventilation (i.e. intubation) or died by day 15. It is not clear at this stage how many patients will be suitable for enrolment. Therefore, there may not be sufficient patient numbers to power the study on clinical outcomes. If the case fatality rate is ~1%, the study will almost certainly not be powered for showing a difference in mortality. If the requirement for ventilation or mortality at 15 days is 5%, the study will require 2440 patients to demonstrate a difference of 2.5% in the primary endpoint. Nonetheless, the investigator group felt that the primary endpoint should be one of clinical significance. There is also value in conducting the study to assess virologic and immunologic outcomes. If viral clearance can be achieved more rapidly, in addition to potentially improving the clinical course, it would have implications for infection control and duration of hospitalisation. The WHO Master Protocol is using a primary endpoint of an ordinal score at day 15: 1. Not hospitalized, no limitations on activities 2. Not hospitalized, limitation on activities; 3. Hospitalized, not requiring supplemental oxygen; 4. Hospitalized, requiring supplemental oxygen; 5. Hospitalized, on non-invasive ventilation or high flow oxygen devices; 6. Hospitalized, on invasive mechanical ventilation or ECMO; 7. Death. To allow harmonisation with these WHO Master Protocol outcomes (https://www.who.int/blueprint/priority-diseases/key-action/COVID-19_Treatment_Trial_Design_Master_Protocol_synopsis_Final_18022020.pdf), the components for the ordinal scale will be part of the data collection. The ASCOT investigator group decided that analysis of these ordinal outcomes is complicated to evaluate any distinguishable/meaningful differences amongst these categories, and thus we have opted for a dichotomous primary endpoint. 2.5.1 Participant timeline See Figure 1 and Table 4 . 4 . Either CXR or CT chest. Initial CXR can be on day 1 or in the prior 24 hours. 5. ECG to be taken before 1 st dose of study drug, and then 4 hours post. 6. ECG and blood glucose level to be performed 24 hours after the 1 st dose of study drug (i.e. before day 2 dosing) 7. Clinical sampling for COVID-19 is a priority over research sampling. If routine clinical sampling swab is available for storage, then these will be stored, and test not repeated. If swabs are not available due to clinical shortage at the institution, then samples should not be collected. 8. Collect 1x EDTA for hydroxychloroquine arms and / or 1x lithium heparin blood tube for LPV/r arms. Refer to the laboratory manual for further information 9. Contact participant on Day 8 to enter data for Day 7 10 . Contact participant on Day 11 to enter data for Day 10 11. Contact participant on Day 16 to enter data for Day 15 12. If site is participating in the PK and Enhanced Biological Optional tier 1 research sampling, then only 1x6mL EDTA tube is required to be collected. Otherwise refer to the laboratory manual 13. Coagulation studies not mandatory, but record any APTT, INR or fibrinogen results preformed as per local practice ✓ = if these tests performed at any other timepoint as part of usual COVID-19 care at site, results to be recorded in the CRF All patients with a positive nucleic acid detection for SARS-CoV-2 will be referred by the pathology laboratory to the site investigator or their delegate (sub-investigator or properly qualified research nurse), as soon as identified. The following information will be transcribed onto a screening log by a member of the study team at the time of referral: date and time the sample was collected, the hospital record number (HRN), name & date of birth (DOB) of the patient and date and time the referral was received. The site investigator or their delegate will approach the doctors of the treating team and ask permission to approach the patient for potential recruitment onto the study and record their response in the screening log. To determine eligibility a screening paper CRF (CRF1) will be completed for all potentially eligible participants. The site investigator will do this using information gathered from the medical record and the patient's treating clinician. If the patient is eligible, the investigator will document this in the medical records. Following completion of CRF1, only patients who are eligible will be approached for an informed consent discussion. For ineligible patients and for patients who decline to participate, data may be able to be collected for observational studies. No identifiable data captured on CRF1 will leave the recruiting site. Due to the stringent measures in infection control in hospitals, verbal consent will be obtained instead of written consent. All patients will be in strict contact and droplet precautions and there will be an imperative to minimise use of personal protective equipment (PPE) by staff due to resource limitations. This has implications for recording of consent: • Bringing a consent form and pen to the bedside and then taking these out of the room will violate the infection control rules. • To minimise PPE use, only one person should enter a room to discuss the study with the patient. Therefore, a witness will not be present, neither will a next of kin be present. However, if an interpreter is required for the consent discussion, both the investigator and interpreter may enter the room together. • It is acceptable to take the Patient Information Sheet and Consent form (PICF) into the room for viewing by the patient, and for these documents to be left in the room. • Taking a photo of the signed consent form using site investigator staff digital phones was considered, but digital devices should not be used (outside of clinical requirements) with PPE. An informed consent discussion will be held with each participant by a site investigator or their delegate. Study information that has been approved by the HREC will be provided in written format and in a language comprehensible to the potential participant, using interpreters if necessary. The participant will be given time to ask questions and consider whether to participate in the research. The PICF will remain in the patient's room, in accordance with infection control rules. The investigator will confirm the patient's agreement to the information detailed in the consent form by signing a separate copy of the form kept outside the isolation room. If phone facilities are available, visual contact can be made with the patient, and the PICF can be provided to the patient in written form, verbal consent may be obtained without entering the room. After allowing the potential participant time to read the PICF, the investigator will answer any additional questions they may have and will obtain verbal agreement to participate in the research. The person must clearly and orally indicate that they consent to participation in the study. The verbal consent will be recorded in both the participant's medical record and study consent form after the site investigator or delegate has left the room. This will state that the terms and conditions were all read and agreed to and all questions asked were answered. The following day, the investigator or clinical team will verbally confirm with the participant that they have consented to participate. A copy of the signed consent form will then be given to the participant either at discharge, via email or sent via post. If a form is not available in a person's own language, the form must be translated verbally by an interpreter. The interpreter should sign the consent form held outside the isolation room that such a verbal and literal translation has been given. Where an interpreter is required, the interpreter will need to use appropriate PPE and follow local hospital policy procedures. Prior to proceeding with randomisation, the investigator who has conducted the consent discussion will document in the medical records a summary of the discussion that includes: a statement that consent was obtained, details of any questions asked and answered and if applicable, that an interpreter was involved. If the inclusion/exclusion criteria are confirmed, and the potential participant is unable to provide consent, then the person responsible/medical treatment decision maker (from this point referred to as person responsible) will be approached. At this time, the most senior member of the research team (investigator) will assess the competency of the person responsible before approaching them and inviting them to consider enrolling the potential patient into the ASCOT trial. If agreeable, the person responsible will be provided with further information about the study, both verbally and in written format (PICF). This will include a description of: ❖ The purpose of the study, ❖ Study procedures, ❖ Possible risks/benefits ❖ Rights and responsibilities of the potential participant, and ❖ Alternatives to participation. The person responsible will be invited to ask questions which will be answered by the investigator, and they will be provided with contact details if they have any further questions. If the person responsible agrees that the potential patient should participate in the study, they will be asked to sign the informed Consent Form. A copy of the form will be given to them to keep. If the person responsible is indecisive about enrolment, they will be given 24 hours to consider the study and will be approached once more the following day. The ASCOT managing trial centre recognises that different state jurisdictions have different requirements regarding surrogate consenting procedures. It is up to each site to consider whether they will submit the person responsible/medical treatment decision maker PICF to their HREC/RGO office, and to ensure jurisdictional approval has been received. To randomise the participant the site investigator or their delegate will log onto the ASCOT database and enter the deidentified details from CRF1, which are required before randomisation and treatment assignment for that participant. Minimal compulsory fields required prior to randomisation are screening number, confirmation of eligibility, age, confirmation of consent. Participants will be randomised in a 1:1:1:1 ratio to the standard of care or treatment arms, where the randomisation schedule will be generated by an independent statistician. Randomisation will be stratified by site and will be in permuted blocks of variable block size. The randomised sequence allocation will only be accessible to the data management group and as outlined in the data management SOP. As this is an open-label study and in the event of medical emergency no unblinding procedures are necessary. Screening activity, to evaluate eligibility will be undertaken as described in section 2.5.2 and will be undertaken whilst the patient is in hospital. It is possible that Day 0 and Day 1 activities may be undertaken on the same day. The activities undertaken at this visit are: • Review of inclusion/exclusion and determine eligibility; • Confirmation of a positive SARS-CoV-2 test within the last 12 days; These activities will occur on the day of randomisation and initiating study therapy. Informed consent must be obtained before any study-specific screening evaluations are performed and should be documented in the participant's medical history (2.5.3.). Any activities that are listed below and which were taken as part of routine care within 2 days of randomisation can be used and does not need to be repeated specifically for this study. Most information will be available from the Hospital Medical History. The evaluations/results that will be performed/recorded: o Research blood samples (3x9mL sodium heparin tubes and 2x9mL ACD tubes); Initial study drug will be administered. Record the time. 4 hours post first dose: • 12 lead ECG at 4 hours post initial dose (this requirement may be removed depending on review after the first 100 participants have been assessed); • For sites involved in the PK component: Research blood sample (1x5mL EDTA for hydroxychloroquine arms and / or 1x5mL lithium Heparin blood tube for LPV/r arms). • For sites involved in the PK component: Research blood sample (1x5mL EDTA for hydroxychloroquine arms and / or 1x5mL lithium Heparin blood tube for LPV/r arms). These activities will be performed whilst the participant is in hospital and prior to study drug dosing: If the participant is discharged either today or any time during the study after this time point, then the site PI or their delegate will contact the participant by phone on days 8, 11, 16 and 28 as outlined in the Schedule of events (table 4) with the exception of weekends and public holidays. The purpose of this contact is to check compliance with the protocol in terms of study drug prescribing and recording any adverse events. After the 4 th dose of study drug and only for sites involved in the PK component the following samples will be taken: o Research blood sample (1x5mL EDTA for hydroxychloroquine arms and / or 1x5mL lithium heparin blood tube for LPV/r arms) 4 hours post 4 th (or 5 th ) study dose; o Research blood sample (1x5mL EDTA for hydroxychloroquine arms and / or 1x5mL lithium heparin blood tube for LPV/r arms) 8 hours post 4 th (or 5 th ) dose; The PK samples may be taken on day 3 after the 5 th dose of study drug, if more practicable for the site staff. These activities will be performed if the participant is in hospital: o Research blood sample (3x9mL sodium heparin tubes and 2x9mL ACD tubes); These activities will be performed if the participant is in hospital: • Any shortness of breath experienced. These activities will be performed if the participant is in hospital: • Review of vital signs; o Research blood samples (3x9mL sodium heparin tubes and 2x9mL ACD tubes). These activities will be performed if the participant is in hospital: • Review of vital signs; • Review of clinical observations, including any adverse events; • ICU status; • Review of routine clinical blood test results including full blood examination (FBE), biochemistry (i.e. EUC, LFTs, CRP); • Clinical blood test, not mandated but highly recommended, lactate, D-dimer, LDH, ferritin, coagulation studies (APTT, INR, fibrinogen), troponin, BNP; • Study drug administration doses and times recorded; These activities will be performed if the participant is still in hospital: • Review of clinical observations, including any adverse events; • ICU status. If the participant was discharged before Day 10 then the PI or their delegate will contact the participant by phone on Day 11 and check: • Current health status; • Number of study drug tablets left; • Targeted side effects (i.e. diarrhoea, nausea, vomiting); • Any shortness of breath experienced. Day 15 These activities will be performed if the participant is in hospital: • Review of clinical observations, including any adverse events; • Review of routine clinical blood test results including full blood examination (FBE), biochemistry (i.e. EUC, LFTs, CRP); • Clinical blood test, not mandated but highly recommended, lactate, D-dimer, LDH, ferritin, coagulation studies (APTT, INR, fibrinogen), troponin, BNP; o Research blood sample (1x9mL SST blood tube); o Research blood samples (3x9mL sodium heparin tubes and 2x9mL ACD tubes. If the participant was discharged before Day 15, then the PI or their delegate will contact the participant by phone on Day 16 and check: • Current health status; • Targeted side effects (i.e. diarrhoea, nausea, vomiting); • Any shortness of breath experienced. These activities will be performed if the participant is in hospital: • Clinical observations, including any adverse events; • Only for sites involved in the enhanced biological component (tier 1): o Research blood sample (1x9mL SST blood tube); o Research blood samples (3x9mL sodium heparin tubes and 2x9mL ACD tubes). If the participant has been discharged prior to Day 28, then the site PI or their delegate will contact the participant by phone on Day 28 and record the following information: • participant status, • current oxygen use (if applicable) At Day 90 or later, site staff will review hospital medical records and/or contact the participant (or GP) to record the following information: • Participant status -alive or dead; • Date of death (if applicable); • Current oxygen therapy (if applicable) CRFs will be filled out within 48 hours of the relevant day. For example, the day 1 CRF will be filled out on day 2-3, day 3 on day 4-5 and day 7 on days 8-9. There will be four tiers for collection of research samples and associated data. All sites will need to collect core clinical data. Sites may opt-in to different parts of the enhanced biological, research biological or PK testing tiers. Core Data These are the core clinical data that contribute to the primary endpoint, key secondary outcomes, and key potential confounders. The procedures/investigations undertaken and recorded as part of this clinical data set are part of routine care -except for the ECGs taken at 4hrs, 24hrs and day 4 post initial drug administration for the first 100 participants. Enhanced biological (tier1) Includes research blood, stool and respiratory sampling. Blood and stool samples for the analysis of potential biomarker assays, immunological responses including but not limited to antibody levels, response to virus and genetic analysis including genome wide association study (GWAS). Genomics is increasingly informing researcher's understanding of disease pathobiology. Large-scale human GWAS studies require large collections of DNA from people exposed to, or infected with, SARS-CoV-2. To identify human genes related to susceptibility or disease outcome, this would require COVID-19 individuals with well-defined clinical phenotypes, as GWAS are case-control studies that compare phenotypes, i.e. mild disease vs severe disease, asymptomatic vs active disease, survivors vs non-survivors. To ensure large sample sizes of individuals with differing clinical phenotypes it is essential to collect DNA from multiple studies, with diverse study designs. For example, DNA from active COVID-19 cases from the ASCOT study and from asymptomatic exposed individuals from household or population studies. Research biological (tier 2) Includes additional blood sampling for PBMC isolation and biobanking. Sites that agree to participate in tier 2 sampling, should also have tier 1 samples collected. PK sampling Blood samples for measurements of serum concentrations of lopinavir/ritonavir and/or hydroxychloroquine will be collected at timepoints specified in Table 4 . Sites can opt to be involved in PK sampling, without being involved in tiers 1 or 2 research sampling or be involved in addition to tiers 1 & 2 research sampling. The participants have the right to choose to withdraw from the study at any time and the investigator may discontinue a participant from the study or from treatment if deemed appropriate at any time. Reasons why a participant may be withdrawn from the study include, but are not limited to: • participant request, • primary treating clinicians request, • participant was enrolled and is ineligible (either arising during the study or was overlooked at time of screening and enrolment). Participants will not be withdrawn due to adverse events. The decision to withdraw a participant from the study must be discussed with the coordinating investigators. If the participant withdraws consent from participating in the study and also withdraws consent for disclosure of future information, no further evaluations will be performed, and no additional data will be collected. The co-ordinating investigators may retain and continue to use any data or samples collected before such withdrawal of consent. Participants that leave against medical advice will continue to be followed until the end of the trial to avoid missing data, if they did not complete treatment their data will be used in the intention-totreat analysis, if they completed treatment their data will be used in the as per protocol analysis. Participants that are lost to follow up will continue to be followed until the end of the trial to avoid missing data, if the participant completed treatment their data will be used in the as per protocol analysis. Participants withdrawn from the treatment by the treating clinicians will continue to be followed up to the end of the trial to avoid missing data and will be used in the intention-to-treat analysis. If a participant is withdrawn the reason will be recorded in the database. The study drug the participant is randomised to will be discontinued if a participant chooses to withdraw from the study. If a participant is admitted to ICU due to progressive disease, the treating clinician can continue treatment using the allocated study drug for a total of 10 days. At the time of ICU admission, ASCOT participants meet the study primary endpoint, and may thereafter be enrolled in other clinical trials if eligible, including randomisation to other interventions or continuation of ASCOT study drugs according to study investigators. At this stage this is an open-ended study given the uncertainties of the epidemiological course of SARS-CoV-2. The trial steering committee will continually assess the epidemiological situation, trial progress and interim results, and emerging external evidence of efficacy of the study and other interventional agents. The trial protocol may be adapted as the situation changes. This project will aim to commence as soon as possible in 2020. There is great uncertainty at this early stage of the epidemic. Until further information becomes available there is not sufficient data to predict likely numbers of patients presenting with COVID-19. Estimated rates of need for ventilation among hospitalised patients have varied. In an early report from China of 1099 hospitalised cases, 5% required ICU admission with 2.3% undergoing invasive ventilation 1 . In Italy, ICU admissions (n=556) represented 16% of all patients (n=3420) who tested positive for COVID-19 11 . The following table provides an example of a 2x2 factorial design assuming relative risk 0.5 by LPV/r and by hydroxychloroquine (HCQ) and no interaction between LPV/r and HCQ. Percentages in each cell are the event rate. Given the 2x2 factorial design, each main comparison (either LPV/r or HCQ) is comparing 3.75% vs 1.875% (across rows, or across columns), then the sample size would be 610 per arm (per cell) with a two-sided significance level (alpha) of 5% and 80% power. The total sample size would be 2440 allowing for two comparisons. We will use the Haybittle-Peto approach for interim analyses. Other rules (e.g., O'Brien-Fleming), while preferable in standard settings, require specification of the number and timing of interim analyses which does not allow for sufficient flexibility at this stage. We note that the Haybittle-Peto approach will be an overly conservative approach throughout, necessary in this situation. The calculations in the below table are for power of 70%, 80% and 90%, and for alpha of 0.05 and 0.045. The 0.45 value is investigated as a conservative estimate to adjust for the interim analyses according to the Haybittle-Peto rule, without knowing a priori the number, timing and type of the interim analyses (i.e., efficacy/ harm/ futility). Numbers refer to total and in each study arm. 2.8.1 Allocation Participants will be randomised in a 1:1:1:1 ratio to active treatment or standard of care treatment arms, using a randomisation schedule generated by an independent statistician produced and uploaded into the database which is available 24 hours per day, 7 days per week. Randomisation will be stratified by site and will be in permuted blocks of variable block size. The randomised sequence allocation will be stored in the database and will not be available to any investigators or member of study staff. The allocation sequence will be generated by a statistician not involved in the day to day trial procedures. Participants will be enrolled by site principal investigators or their delegates (research nurse or co-investigator). The person enrolling the participant will, following obtaining verbal informed consent, obtain the treatment allocation by logging onto the electronic data capture system, completing the required fields before the system will allow randomisation and subsequent treatment allocation. This is an open-label study, but researchers assessing the laboratory outcomes will be blinded to treatment allocation. Although blinding was considered, the added complications and expense were deemed prohibitive. Furthermore, no placebo of LPV/r was available from AbbVie at the time of trial design. Source documents are where data are first recorded, and from which participants' CRF data are obtained. These include but are not limited to, hospital records both electronic & paper (which will include medical history, previous and current medications, any relevant radiography test, blood test results, haemodynamic parameters and medical correspondence) and electronic clinic records (which will include vital status, recent medical history and relevant blood culture results). A further data source will be through telephone conversations with the study participant or GP. Storage and archiving of study documents (CRFs and consent forms) will be the responsibility of the site principal investigator and will remain at the site of recruitment and retained for 15 years. All study participants will be allocated a unique number at time of screening (screening number), this screening number will be added to all the CRFs for that participant. The participants will also have their HRN recorded on the CRFs as this information will be required to ensure the correct medical record is accessed during medical record reviews. The date and time will be captured on the CRF for all telephone conversations with study participants or GP. Protocol deviations will be recorded in the participant record (source document) and on the CRF and must be reported to the Site Principal Investigator, who will assess for seriousness. In this study, protocol deviations collected for this study will be limited to: • Missed visits as outlined in the Schedule of Events Those deviations deemed to affect to a significant degree rights of a trial participant or the reliability and robustness of the data generated in the clinical trial will be reported as serious breaches. Reporting will be done in a timely manner (Site Principal Investigator to report to the Sponsor within 72 hours and to the Site RGO within 7 days; Sponsor to review and submit to the approving HREC within 7 days). Where non-compliance significantly affects human participant protection or reliability of results, a root cause analysis will be undertaken and a corrective and preventative action plan prepared. Where protocol deviations or serious breaches identify protocol-related issues, the protocol will be reviewed and, where indicated, amended. Data for this study will be recorded via a secure, Electronic Data Capture (EDC) web-based system using the eCRFs. It will be transcribed by the site PI or their delegate from the paper CRFs onto the eCRF (in no case is the eCRF to be considered as source data for this trial). Data will be stored in a re-identifiable manner in the database, using a unique screening number for each patient. The database will contain validation ranges for each variable to minimise the chance of data entry errors. An audit trail will maintain a record of initial entries and changes made; reasons for change; time and date of entry; and username of person who made the change. Data queries will be raised by the project manager and study monitor, and missing data or suspected errors will be raised as data queries and resolved prior to database lock and analysis. The database will contain in-line capability so that these queries and answers are logged as part of the audit trail. For each potential participant screened (even those who are not eligible), the screening eCRF will be completed by the site PI or their delegate. For each participant enrolled, eCRFs must be completed. This also applies to records for those patients who fail to complete the study. The site PI should ensure the accuracy, completeness and timeliness of the data reported to the sponsor in the eCRFs and in all required reports. A comprehensive validation check program will verify the data and automatically generate discrepancies for resolution by the investigator. Manual discrepancies can also be raised if necessary. In addition, accurate and reliable data collection will be assured by verification of the eCRFs against the investigator's records by the study monitor (source document verification), and the maintenance of medication compliance will be captured in the CRFs from the participant's medication chart (source document) by the investigator. Storage and archiving of hard-copy study documents (CRFs and consent forms) will be the responsibility of the principal investigator at each site and will remain at the site of recruitment following local security guidelines. Hard-copy study documents will be kept for a minimum of 15 years and confidentially destroyed at the end of this period only with the express consent of the study sponsor. Participant confidentiality is strictly held in trust by the participating investigators, research staff, and the sponsoring institution and their agents. This confidentiality is extended to cover testing of biological samples and genetic tests in addition to the clinical information relating to participating participants. The trial protocol, documentation, data and all other information generated will be held in strict confidence. No information concerning the trial or the data will be released to any unauthorised third party, without prior written approval of the sponsoring institution. Authorised representatives of the sponsoring institution may inspect all documents and records required to be maintained by the Investigator, including but not limited to, medical records (office, clinic or hospital) and pharmacy records for the participants in this trial. The clinical trial site will permit access to such records. All laboratory specimens, evaluation forms, reports and other records that leave the site will be identified only by the Participant Identification Number to maintain participant confidentiality. Clinical information will not be released without written permission of the participant, except as necessary for monitoring by HREC or regulatory agencies. Data will be reported in accordance with the CONSORT guidelines for reporting of randomised trials. Proportions will be compared between treatment groups with Fisher's exact or χ 2 tests, and the absolute difference in proportions reported with corresponding 95% confidence intervals. All-cause mortality will be presented in a Kaplan-Meier graph. The primary analysis of both primary and secondary endpoints will be according to modified intention to treat principles (all participants with data available for the endpoint will be analysed according to the treatment allocation, regardless of what treatment they received). No assumptions will be made about those with missing data. A secondary per-protocol analysis of all endpoints will be conducted. The per protocol population is defined as 1) for the control group: did not receive any LPV/r or hydroxychloroquine; 2) for the intervention group: received at least 80% of possible doses of study drug; 3) has available data. We will perform the following subgroup analyses: 1. Age ≥65 or <65 years. Early experience with SARS-CoV-2 infection is that older age is associated with poorer outcomes. There is biological plausibility that early treatment to reduce viral replication will be more effective than later treatment when pulmonary pathology may already be evident. Should the result for a particular main effect (e.g., LPV/r vs no LPV/r) cross the designated boundary at an interim analysis, consideration will be given to termination of the study of that intervention (e.g., cease recruitment to the two LPV/r arms and randomize new patients to HCQ or Standard care only). Details will be provided in the DSMB charter. 3. Are there any other factors that may impact on the feasibility / usefulness of the study? E.g., rate of enrolment, unexpected low rate of outcomes, unable to fund, protocol violations etc. 4. Should the study continue in light of emerging data on treatment of SARS-CoV-2? In addition to the planned interim analyses, the DSMB will monitor the emerging literature on the effect of antiviral and other treatments on COVID-19. If data are published which demonstrate that one of the trial interventions (LPV/r or hydroxychloroquine) are clearly superior to standard of care, then the DSMB will consider recommending dropping the standard of care arm or ceasing the trial entirely. A study with three treatment arms would address the comparative benefit of LPV/r vs hydroxychloroquine vs both drugs combined. If either LPV/r or hydroxychloroquine are clearly harmful, then the relevant treatment arms could be dropped. The trial steering committee will make the final decision on these matters. After 100 participants have been randomised, the DSMB will review data on QTc and gastrointestinal tolerability of study drug regimens. Recommendations can then be made as to safety of the study drug regimens and what ongoing monitoring requirements will be for subsequent patients. In particular, a recommendation will be sought for whether an ECG 4 hours post initial drug dose is still required. The primary endpoint data will not be assessed at this review after 100 participants. The trial is currently designed with a frequentist analysis framework. This approach has been necessary given the time constraints in designing and commencing recruitment as soon as possible. However, the trial steering committee will consider moving to a Bayesian adaptive trial approach after further consultation. No interim analyses will be performed until such a decision has been made. If it is decided to convert to a Bayesian adaptive trial approach, no interim analyses will be performed until a pre-specified Bayesian adaptive analysis plan has been designed and agreed upon. This trial will be centrally co-ordinated from the Doherty Institute. The study will also have input from the Australasian Society for Infectious Diseases Clinical Research Network. An independent DSMB will be established to review the progress of the study and monitor adherence to the protocol, participant recruitment, outcomes, complications, and other issues related to participant safety. They will also monitor the assumptions underlying sample size calculations for the study and alert the investigators if they see substantial departures as the data accumulate. A copy of recommendations from the DSMB will be sent to respective HRECs. The DSMB will be composed of experts in infectious diseases, biostatistics, clinical trials, virology and immunology. The DSMB members will all be independent of the investigators (none of them will be chief investigators or site investigators). The DSMB will make recommendations as to whether the study should continue or be terminated, consider participant safety or other circumstances as grounds for early termination, including either compelling internal or external evidence of treatment differences or feasibility of addressing the study hypotheses (e.g. poor participant enrolment, poor adherence). The DSMB will operate under the rules of an approved charter that will be written and reviewed at the organisational meeting of the DSMB. Study monitoring will be provided by the responsible monitor(s) in accordance with the Monitoring Plan and principles of ICH GCP. The monitoring plan will be developed and will likely mainly rely on central monitoring with limited site visits depending on resources and number of sites. All study drugs are licensed for use in Australia with established safety profiles. An Adverse Event (AE) is defined as any untoward medical occurrence in a patient or clinical trial participant administered a medicinal product/s that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of the study drug, whether or not causally linked to the investigational drug. An adverse event that is judged by the reporting medically qualified professional as having a reasonable suspected causal relationship with the trial drug. The information contained in an approved Australian Product Information contains the information used to determine what adverse reactions are to be considered expected adverse reactions and, on the frequency, and nature of those adverse reactions. For this study, specific adverse events (refer to section 2.4.2) will be collected for all participants as pre-defined secondary outcomes and are defined in Table 5 . Enzyme investigations and imaging only required for pancreatitis if clinically indicated. Where clinically appropriate, study drug should be ceased. Consider a SUSAR as any SAE that is both suspected to be related to the study drug treatment and is unexpected (i.e. not consistent with the available RSI contained in the approved Product Information). A safety issue that could adversely affect the safety of participants or materially impact on the continued ethical acceptability or conduct of the trial. A SSI is a new safety issue or validated signal considered by the Sponsor in relation to the study drug(s) that requires urgent attention. This may be because of the seriousness and potential impact on the benefit-risk balance of the investigational study drug, which could prompt regulatory action and/or changes to the overall conduct of the clinical trial, including the monitoring of safety and/or the administration of the study drug product A measure required to be taken in order to eliminate an immediate hazard to a participant's health or safety. This is a type of SSI that can be instigated by either the investigator or sponsor and can be implemented before seeking approval from HRECs or institutions The principal site investigator will make a judgement regarding whether an adverse event is clinically significant and whether or not it is related to the allocated treatment. The degree of certainty with which an adverse event is attributable to treatment or an alternative cause will be determined by how well the event can be understood in terms of: o Temporal relationship with the administration of the treatment or cessation of treatment o Reactions of a similar nature previously observed in the individual or others following treatment The relationship of the adverse event to treatment will be specified as follows: In the PI's opinion, there is not a causal relationship Unlikely The temporal association between treatment and the adverse event is such that treatment is not likely to have any reasonable association. The adverse event could have been caused by treatment. The adverse event follows a temporal sequence from the time of treatment and cannot be reasonably explained by the known characteristics of the participant's clinical presentation/history. The adverse event follows a reasonable temporal sequence from the time of treatment or reappears when the treatment is repeated. Site Principal Investigator Reporting Procedures: The Site PI is responsible for recording all safety events in the source document. The Site PI is responsible for expedited reporting (within 24 hours of becoming aware of the event) to the Sponsor the following local safety events: • USMs • SUSARs • All SAEs except: o Those not thought to be related to the study drug (e.g. death from respiratory failure -expected for COVID-19); The Site PI is also responsible for reporting SSIs, local USMs and local SUSARs to their research governance office within 72 hours of becoming aware of the event and in accordance with their local governance authorization. The minimum amount of information that the site investigator must complete on the initial report is: • title of the event -avoid colloquialisms or abbreviations; • date started; • reason the event is considered an SAE; • causality relationship to investigational drug/device. The PI or designee should complete the SAE form and send to: BaCT Safety team: Safety_BaCT@petermac.org ASCOT Coordinating Centre: ascot-team@unimelb.edu.au Sponsor Reporting Procedures: The Sponsor must assess and categorise the Safety Reports received from Investigators and report these to all Site Principal Investigators, the approving HREC and TGA in accordance with the NHMRC's 'Safety monitoring and reporting in clinical trials involving therapeutic goods' (November 2016) and any additional requirements of the approving HREC. All safety reports must clarify the impact of the safety event on participant safety, trial conduct and trial documentation. The Sponsor is responsible for the following reporting to PIs, the HREC(s) and TGA: 1. All SSIs that meet the definition of a USM within 72 hours of becoming aware of the issue. 2. All other SSIs within 15 calendar days of instigating or becoming aware of the issue 3. For SSIs leading to an amendment of trial documentation: a. Submit details of the SSI without undue delay and no later than 15 calendar days of becoming aware of the issue. b. Submit amendment to the HREC without undue delay. 4. For SSIs leading to temporary halt or early termination of a trial for safety reasons: a. Communicate reasons, scope of halt, measures taken, further actions planned without undue delay and no later than 15 calendar days of decision to halt. b. For a temporary halt, notify the PIs, HREC and TGA when the trial restarts, including evidence that it is safe to do so. The Sponsor will also report SUSARs to the TGA as follows: 1. Fatal or life-threatening SUSARs immediately, but no later than 7 calendar days after being made aware of the issue (follow up info within a further 8 calendar days) 2. All other SUSARs no later than 15 calendar days of being made aware of the issue The Sponsor is responsible for providing information to the approving HREC and to investigators of any updated Product Information for the study drugs. The study will be conducted according to the declaration of Helsinki, the NHMRC criteria for the ethical conduct of research in humans and the principles of Good Clinical Practice 12 . The therapeutic agents lopinavir/ritonavir (LPV/r) oral solution and hydroxychloroquine used in this study are registered for use in Australia and New Zealand. The Mylan brand of LPV/r has only been registered in the EU. It is currently in the process of being registered in the US through the FDA. LPV/r has proven safe in the HIV setting. Hydroxychloroquine is widely used for autoimmune conditions. Chloroquine is widely used as an anti-malarial agent. Approval will be sought from relevant human research ethics committees (HRECs) for all sites. The study protocol, information statements, consent forms, and any other documents required for ethics approval will be submitted to the relevant HRECs for approval before the study commences. Each HREC reviewing the protocol must be properly constituted according to NHMRC requirements and have the capacity to review the study. Approvals must specify the study title, version numbers, and identify all documents reviewed and state the date of review. No amendments to, or deviations from, the protocol must be initiated without prior written approval from the relevant HREC. The exceptions to this are: • administrative aspects that have no bearing on participants; • the need to address regulatory requirements; and/or, The trial steering committee will be the custodians of the final trial dataset. No-one outside the trial steering committee will be given access to the data without the permission of the trial steering committee. No identifying data will be given to any third parties at any stage. Following study close out and locking of the database, it will be stored on the servers of the sponsor. Harmonisation of data collection as detailed in 2.15.1 should facilitate data sharing. The study will have an ethos of appropriate sharing of data to contribute towards global datasets. At study sites where REMAP-CAP is open for recruitment, participants enrolled in ASCOT and progressing to ICU admission or need for invasive and noninvasive ventilation will be identified to REMAP-CAP study staff as being enrolled in ASCOT. The ASCOT unique study number will be communicated to REMAP-CAP to allow linkage of data. At study sites where SPRINT-SARI is collecting observational data, data from participants enrolled in ASCOT can be shared with SPRINT-SARI. No identifiable data will be provided. Data collected may be shared in aggregate form in real time to inform the clinical community and facilitate discussion of clinical management of patients. These data will only be presented for all participants in total without identification of allocated treatments. Examples of such data will be baseline characteristics, investigation results, hospitalisation and ICU status, need for invasive or non-invasive ventilation, and mortality. The trial results will be communicated to all site investigators by teleconference prior to publication or presentation. The trial results will also be submitted for presentation at national and international meetings and publications submitted to a peer reviewed scientific journal, irrespective of the results. A plain-language summary of the trial results will be made available to individual participants upon request. Primary and senior authorship will be determined by the study steering committee. The authorship of the paper will include all of the Steering Committee who meet ICJME criteria for authorship. Hospitals contributing at least one case for analysis will nominate a locally determined coordinating investigator for inclusion, in order of number of participants enrolled. All hospitals and participating organisations with protocols enacted will be listed as 'ASCOT group'. The ASCOT group will consist of all named site investigators and will be listed in the collaborators section of the paper. The author byline will include 'for the ASID Clinical Research Network'. These appendices will be updated as required during the study See Appendix 1 (standalone document) for list of trial sites and site principal investigators. There will be 4 tiers for collection of data and samples (see 2.5.6). The Core data only includes recording of clinical, outcome, treatment data and results from laboratory testing and does not involve storage of samples. The Enhanced biological, Research biological and PK data and samples includes the collection and storage of some biological samples. The collection, processing, storage and shipping of biological samples will follow local standard operating procedures and regulations for handling and transporting clinical specimens containing infectious materials. These details will align with the Sentinel Travellers Research Preparedness Platform for Emerging Infectious Diseases (SETREP-ID) Biological Specimen Standard Operating Procedures. These samples and data collection will be dependent on site capacity and participant consent obtained for enhanced sample collection, storage and sharing. The trial will be overseen by the Trial Steering Committee that will include: Steven Tong, Justin Denholm, Joshua Davis, David Paterson, representatives from each participating jurisdiction, the ASID CRN, and a biostatistician. The trial management committee will oversee the day to day aspects of the trial. This committee will include: Steven Tong, Justin Denholm, Joshua Davis, clinical trial manager and project officers. Ongoing funding is being sought through philanthropy and applications to MRFF and the Victorian Medical Research Acceleration Fund. recommend sourcing the oral solution from local pharmacy. If there is no access for local sites to secure commercially available oral solution, then the Sponsor recommends crushing the lopinavir/ritonavir study tablets. Sites are to contact the Sponsor for further guidance and information regarding the crushing of lopinavir/ritonavir tablets. Swallowing difficulties: 1. Administer 5mL of suspension orally The liquid has an unpleasant taste. The use of ice chips before and after the dose may numb the taste buds or mix the dose with chocolate syrup to mask the taste Feeding tube: 1. Give immediately after a bolus feed or stop the continuous feed 2. Flush the tube with 30 mL of water 3. Draw 5mL into an enteral syringe and dilute with at least an equal volume of water 4. Mix well and give via the nasogastric feeding tube 5. A white residue or cloudy solution may be seen but will not clog the tube 6. Flush the tube with 30 mL of water and restart the feed Due to the high content of propylene glycol and ethanol in the oral suspension, a PVC / silicone feeding tube should be used due to incompatibility with polyurethane. There is adequate absorption of lopinavir when the oral liquid is given through nasogastric or PEG tubes and reduced absorption when given through jejunal tubes. Clinical Characteristics of Coronavirus Disease 2019 in China Treatment of Middle East Respiratory Syndrome with a combination of lopinavir-ritonavir and interferon-beta1b (MIRACLE trial): study protocol for a randomized controlled trial Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort study Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19 In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Short-course primaquine for the radical cure of Plasmodium vivax malaria: a multicentre, randomised, placebo-controlled noninferiority trial Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury Critical Care Utilization for the COVID-19 Outbreak in Lombardy, Italy: Early Experience and Forecast During an Emergency Response. JAMA 2020. 12. International Conference on Harmonisation of technical requirements for registration of pharmaceuticals for human u. ICH harmonized tripartite guideline: Guideline for Good Clinical Practice 3. Mild vs moderate severity at presentation. Initial severity at presentation may predict the later clinical course and there may be a differential effect of antiviral treatment. The absolute improvement in clinical outcomes may be more evident in the moderate severity group due to a higher event rate. a. Mild severity at presentation is defined as: SaO2≥95% on room air AND not requiring supplemental oxygen AND not tachypnoeic (respiratory rate <24 breaths/min) b. Moderate severity at presentation is defined as SaO2≤94% on room air OR requiring supplemental oxygen OR tachypnoeic (respiratory rate ≥24 breaths/min) 4 . Baseline use of ACE inhibitors or ATIII blockers. These medications affect the renin angiotensin aldosterone system pathway, which may also be affected by SARS-CoV-2, which uses ACE2 as its cellular receptor. Use of these medications may result in differential susceptibility to SARS-CoV-2 infection, with the direction of effect uncertain. These are different patient groups with regards to underlying comorbidities and risk for severe sepsis. Patients will be considered immunosuppressed if in receipt of immunosuppressing medication considered by the site investigator to be equivalent to ≥20 mg of prednisolone for ≥2 weeks, or with a known haematological malignancy.6. Those with end stage kidney disease (ESKD, meaning receipt of haemodialysis or peritoneal dialysis) at enrolment. The pharmacokinetics of hydroxychloroquine are uncertain in this population, the risk of drug-related adverse events may be higher, and the efficacy of the study drugs maybe either better (higher blood levels) or worse (underlying comorbidities leading to poor outcomes regardless of adjunctive therapies). 15. The pharmacokinetics of hydroxychloroquine are uncertain in this population, the risk of drug-related adverse events may be higher, and the efficacy of the study drugs maybe either better (higher blood levels) or worse (underlying comorbidities leading to poor outcomes regardless of adjunctive therapies). The Data and Safety Monitoring Board (DSMB) will not conduct an interim analysis until a decision has been made on whether to convert to an adaptive platform trial framework. If it is decided to not covert to an adaptive platform trial framework, an interim analysis can occur after 200 participants have been randomised. There will be continued review of the need for further interim analyses.The interim analysis will review outcome data and answer the following questions:1. Are there any significant safety issues that may present an ethical issue in continuing the study? This may include adverse events, but also study conduct and protocol violations 2. Is there overwhelming data suggesting the superiority of one arm that may present an ethical issue in continuing the study? The interim analyses will be adjusted according to Haybittle-Peto, separately for the LPV/r and HCQ main effects, using an overall twosided 5% significance level across the interim and final analyses for each main effect.• the need to eliminate immediate hazards to the participants.The Sponsor will inform the HREC of the following:• all protocol amendments, informed consent changes or revisions of other documents originally submitted for review; • serious and/or unexpected adverse events • new information that may affect the safety of the participants or the proper conduct of the trial; • annual updates of study progress • termination of the study including provision of a final study report. Both LPV/r and Hydroxychloroquine have been used in millions of people worldwide over decades, and have established safety profiles. However, with both of these drugs there is a small risk of severe and possibly even fatal adverse events (see section 1.2.4 for more detail). We believe this small risk is justified because of the potential for benefit, and the context that the enrolled patients have a serious infection with has a 1.5%-7% chance of mortality (hundreds of times higher than the risk of severe AEs from the study drugs). Furthermore, eligibility criteria and monitoring mitigate the risk of severe AEs, and patients have provided informed consent, with the knowledge of the possibility of these AEs. See Section 2.5.3. In the event of shortages of either of the investigational product LPV/r and hydroxychloroquine at participating trial sites, then treatment arms involving that drug will be suspended at those sites. Randomisation to standard of care or monotherapy with the remaining drug will continue. If both drugs are not available at participating trial sites, then the trial will be suspended at those sites.The trial steering committee will liaise closely with drug providers to secure drug supply during the course of the study. Although LPV/r and hydroxychloroquine are licensed for use in Australia and New Zealand, they will be used outside their approved indications. Hence a Clinical Trials Notification (CTN) will be lodged with the Therapeutic Goods Administration (TGA) for all Australian sites. Given the importance of data sharing with other studies being concurrently conducted, data collection and protocols are being harmonised with:• WHO Master Protocol: https://www.who.int/blueprint/priority-diseases/keyaction/multicenter-adaptive-RCT-of-investigational-therapeutics-for-COVID-19.pdf The following information has been provided by the REMAP-CAP group and is in line with their current practises. The information applies to 200mg tablets.3.4.1.1 For enteral feeding tubes: 1. Give immediately after a bolus feed or stop the continuous feed. 2. Flush the tube with 30 mL of water.3. Crush the tablet to a fine powder using a mortar and pestle or a tablet crusher. 4. Add 10 mL of water to the powder and mix well (the tablet does not disperse easily). 5. Draw the mixture into the enteral syringe. 6. Rinse the crushing device with 10ml of water, then repeat with another 10ml (total of 20ml) and draw into the enteral syringe, to ensure that all of the medicine is removed. 7. Give the mixture (~30mL) immediately into the enteral feeding tube. 8. Rinse the enteral syringe with a further 10 mL of water to ensure the entire dose is given. 9. If other medicines are given, flush the tube with at least 5 mL of water between each medicine. 10. After the final medicine is given, flush the tube with 30 mL of water. 11. Restart the continuous feed immediately after dosing.Smaller volumes can be used to accommodate fluid-restriction.3.4.1.2 For swallowing difficulties: 1. Crush the tablet with a mortar and pestle or a tablet crusher. 2. Add 10 to 20 mL of water and mix well. 3. Draw the mixture into an oral dispenser/syringe. 4. Rinse the crushing device with 10ml of water, then repeat with another 10ml (total of 20ml) and draw into the oral dispenser/syringe, to ensure that all of the medicine is removed. 5. Give the mixture immediately. 6. Rinse the oral dispenser/syringe with a further 10mL of water and give to the patient, to ensure the entire dose is given.If the person cannot swallow thin fluids (i.e. is an aspiration risk) or the very bitter taste is unacceptable, crush the tablet and mix with a spoonful of yoghurt or apple puree. The Sponsor's first preference is to use commercially available oral suspension Lopinavir 80mg/Ritonavir 20mg per mL suspension. A limited number of lopinavir/ritonavir oral suspension stock has been secured from the National Medical Stockpile (Australian Government). Site access to this oral formulation is outlined in the IMP Management Plan. If during the study, the oral suspension is no longer available from the Sponsor, then we